COMPANY PROFILE // THE 014 REPORT
Scilex Holding Co
SCLX (Nasdaq) · SCLXW (Nasdaq) · Formerly: Scilex Holding Company/DE; Vickers Vantage Corp. I
Assembled from 3 government sources in 2.9 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2026-11-17 and 3 more times (last 24 months).
- AmberNT 10-Q filed on 2026-11-17: notice that a periodic report would be late (3 such notices in 24 months).
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2024-11-22 (last 24 months).
- InfoGLEIF: no direct parent reported; reporting exception reason NO_KNOWN_PERSON.
✓ SEC filings✓ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Scilex Holding Co is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Palo Alto, CA; listed as SCLX (Nasdaq), SCLXW (Nasdaq).[source] It reported revenue of $30.3 million for the fiscal year ended 2025-12-31.[source] It has filed 91 documents with the SEC in the last 12 months; the latest is a NT 10-Q, filed 2026-11-17.[source] Its largest institutional holders on 13F filings are VANGUARD CAPITAL MANAGEMENT LLC, BlackRock, Inc., VANGUARD FIDUCIARY TRUST CO (as of 2026-06-30).[source] Seraphix flags 3 items from these records: 8-K Item 4.01 filed; 8-K Item 3.01 filed; NT 10-Q filed on 2026-11-17.[source]
- red0
- amber3
- info1
- VANGUARD CAPITAL MANAGEMENT LLC$9.3M
- BlackRock, Inc.$4.0M
- VANGUARD FIDUCIARY TRUST CO$1.3M
- STATE STREET CORP$1.1M
- UBS Group AG$827K
- Themes Management Co LLC$627K
- NORTHERN TRUST CORP$477K
- Balyasny Asset Management L.P.$231K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Ji Henry · CEO and President (Director,Officer) · latest Form 4 2025-10-09 · filing · LinkedIn search
- Ma Stephen Hoi · CFO and COO (Director,Officer) · latest Form 4 2025-10-09 · filing · LinkedIn search
- Chun Jay · Director · latest Form 4 2025-10-09 · filing · LinkedIn search
- Followwill Dorman · Director · latest Form 4 2025-10-09 · filing · LinkedIn search
- Wu Yue Alexander · Director · latest Form 4 2025-10-09 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Paul Hastings LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-06-30
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001820190 | source |
| LEI | 529900SPEA2C7YTTYP45 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-02-02 · in 74 days · LEI next renewal (529900SPEA2C7YTTYP45)
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
ADDRESS · ZIP CODE
Location context
At the same address (2)
- Semnur Pharmaceuticals, Inc. · SEC registrant
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Semnur Pharmaceuticals, Inc. · Ji Henry
- Semnur Pharmaceuticals, Inc. · Ma Stephen Hoi
- Semnur Pharmaceuticals, Inc. · Chun Jay
- Semnur Pharmaceuticals, Inc. · Followwill Dorman
- Semnur Pharmaceuticals, Inc. · Wu Yue Alexander
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-17 filing NT 10-Q · SEC EDGAR
- 2026-11-17 filing 8-K items 4.01 · SEC EDGAR
- 2026-09-29 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-08-24 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-08-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-12 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-07-22 filing 8-K items 1.01,2.01,9.01 · SEC EDGAR
- 2026-07-07 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-07-06 filing 8-K items 1.01,3.02,7.01,9.01 · SEC EDGAR
- 2026-06-30 filing S-8 · SEC EDGAR
- 2026-06-29 filing 8-K items 1.01,3.02 · SEC EDGAR
- 2026-06-26 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-06-24 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2026-06-11 filing EFFECT · SEC EDGAR
- 2026-06-09 filing CORRESP · SEC EDGAR
- 2026-06-09 filing UPLOAD · SEC EDGAR
- 2026-06-02 filing S-3 · SEC EDGAR
- 2026-05-22 filing EFFECT · SEC EDGAR
- 2026-05-20 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-20 filing CORRESP · SEC EDGAR
- 2026-05-15 filing NT 10-Q · SEC EDGAR
- 2026-05-11 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-05 filing DEFA14A · SEC EDGAR
- 2026-05-05 filing 8-K items 1.01,7.01,9.01 · SEC EDGAR
- 2026-04-30 filing ARS · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-30 filing CORRESP · SEC EDGAR
- 2026-04-28 filing 8-K items 1.01 · SEC EDGAR
- 2026-04-24 filing UPLOAD · SEC EDGAR
- 2026-04-16 filing S-3 · SEC EDGAR
170 earlier entries
- 2026-04-10 filing Annual report (10-K)
- 2026-04-01 filing NT 10-K
- 2026-03-13 filing 8-K items 7.01,9.01
- 2026-03-13 filing 8-K items 7.01,9.01
- 2026-02-23 filing 424B3
- 2026-02-23 filing 424B3
- 2026-02-23 filing 424B3
- 2026-02-20 filing 8-K items 1.01,3.02,9.01
- 2026-02-20 filing UPLOAD
- 2026-02-13 filing DRS
- 2026-02-09 filing S-8
- 2026-02-03 filing 8-K items 3.03,5.03,9.01
- 2026-02-02 filing 8-K items 1.01,9.01
- 2026-01-14 filing SCHEDULE 13D/A
- 2026-01-08 filing SCHEDULE 13D/A
- 2026-01-06 filing RW
- 2025-12-31 filing SCHEDULE 13D/A
- 2025-12-30 filing 8-K items 7.01
- 2025-12-29 filing EFFECT
- 2025-12-29 filing 424B3
- 2025-12-23 filing CORRESP
- 2025-12-22 filing 8-K items 7.01
- 2025-12-17 filing 424B3
- 2025-12-17 filing 424B3
- 2025-12-17 filing 424B3
- 2025-12-17 filing 8-K items 1.01,2.03,9.01
- 2025-12-16 filing Registration (S-1)
- 2025-12-12 filing 424B3
- 2025-12-12 filing 424B3
- 2025-12-12 filing 424B3
- 2025-12-12 filing 8-K items 1.01,2.03,9.01
- 2025-12-11 filing 424B3
- 2025-12-11 filing 424B3
- 2025-12-11 filing 424B3
- 2025-12-11 officer change 8-K items 5.02,5.07
- 2025-12-05 filing 424B3
- 2025-12-05 filing 424B3
- 2025-12-05 filing 424B3
- 2025-12-05 filing 8-K items 1.01,2.03,9.01
- 2025-12-04 filing UPLOAD
- 2025-12-01 filing SCHEDULE 13D
- 2025-12-01 filing 424B3
- 2025-12-01 filing 424B3
- 2025-12-01 filing 424B3
- 2025-12-01 filing 8-K items 2.01,7.01,9.01
- 2025-11-24 filing 424B3
- 2025-11-24 filing 424B3
- 2025-11-24 filing 424B3
- 2025-11-24 filing 8-K items 1.01,3.02,9.01
- 2025-11-14 filing 424B3
- 2025-11-14 filing 424B3
- 2025-11-14 filing 424B3
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-11-07 filing Proxy statement
- 2025-11-04 filing 424B3
- 2025-11-04 filing 424B3
- 2025-11-04 filing 424B3
- 2025-11-04 filing 8-K items 1.01,7.01,9.01
- 2025-10-31 filing 424B3
- 2025-10-31 filing 424B3
- 2025-10-31 filing 424B3
- 2025-10-31 filing 8-K items 1.02,9.01
- 2025-10-28 filing PRE 14A
- 2025-10-14 filing D
- 2025-10-14 filing SCHEDULE 13D/A
- 2025-10-09 insider First Form 3/4/5 on record for Ji Henry (CEO and President)
- 2025-10-09 insider First Form 3/4/5 on record for Ma Stephen Hoi (CFO and COO)
- 2025-10-09 insider First Form 3/4/5 on record for Chun Jay (Director)
- 2025-10-09 insider First Form 3/4/5 on record for Followwill Dorman (Director)
- 2025-10-09 insider First Form 3/4/5 on record for Wu Yue Alexander (Director)
- 2025-10-07 filing 424B3
- 2025-10-07 filing 424B3
- 2025-10-07 filing 424B3
- 2025-10-07 officer change 8-K items 5.02
- 2025-10-02 filing SCHEDULE 13D
- 2025-10-02 filing 424B3
- 2025-10-02 filing 424B3
- 2025-10-02 filing 424B3
- 2025-10-01 filing 8-K items 1.01,3.02,9.01
- 2025-09-29 filing 424B3
- 2025-09-29 filing 424B3
- 2025-09-29 filing 424B3
- 2025-09-26 filing 8-K items 1.01,2.01,7.01,9.01
- 2025-09-26 filing SCHEDULE 13D
- 2025-09-26 filing 8-K items 1.01,2.01,3.02,7.01,8.01,9.01
- 2025-09-26 officer change 8-K items 5.02,9.01
- 2025-08-29 filing CORRESP
- 2025-08-21 filing 424B3
- 2025-08-21 filing 424B3
- 2025-08-21 filing 424B3
- 2025-08-21 officer change 8-K items 5.02,9.01
- 2025-08-20 filing UPLOAD
- 2025-08-14 filing 424B3
- 2025-08-14 filing 424B3
- 2025-08-14 filing 424B3
- 2025-08-13 filing Quarterly report (10-Q)
- 2025-08-04 filing Registration (S-1)
- 2025-07-23 filing 424B3
- 2025-07-23 filing 424B3
- 2025-07-23 filing 424B3
- 2025-07-23 filing 8-K items 1.01,9.01
- 2025-07-23 filing 8-K items 1.01,3.02,9.01
- 2025-06-24 filing 424B3
- 2025-06-24 filing 424B3
- 2025-06-24 filing 424B3
- 2025-06-23 filing 8-K items 7.01,9.01
- 2025-06-23 filing 8-K items 5.07,9.01
- 2025-06-04 filing 8-K items 7.01,9.01
- 2025-05-16 filing ARS
- 2025-05-16 filing Proxy statement
- 2025-05-15 filing 424B3
- 2025-05-15 filing 424B3
- 2025-05-15 filing 424B3
- 2025-05-14 filing Quarterly report (10-Q)
- 2025-05-14 filing 424B3
- 2025-05-14 filing 424B3
- 2025-05-14 filing 424B3
- 2025-05-13 filing EFFECT
- 2025-05-13 filing EFFECT
- 2025-05-13 filing EFFECT
- 2025-05-12 officer change 8-K items 5.02,9.01
- 2025-05-07 filing POS AM
- 2025-05-07 filing POS AM
- 2025-05-07 filing POS AM
- 2025-04-30 filing 8-K items 8.01,9.01
- 2025-04-29 filing 10-K/A
- 2025-04-22 filing 8-K items 7.01,9.01
- 2025-04-21 filing 8-K items 1.01,9.01
- 2025-04-15 filing 8-K items 3.03,5.03,9.01
- 2025-04-11 filing 8-K items 7.01,9.01
- 2025-04-01 filing S-8
- 2025-03-31 filing Annual report (10-K)
- 2025-03-20 filing 424B3
- 2025-03-20 filing 424B3
- 2025-03-20 filing 8-K items 5.07,9.01
- 2025-03-10 filing 8-K items 7.01,9.01
- 2025-03-05 filing 424B3
- 2025-03-03 filing 424B3
- 2025-03-03 filing 424B3
- 2025-03-03 filing 8-K items 1.02
- 2025-03-03 filing 8-K items 1.01,9.01
- 2025-02-27 filing 424B3
- 2025-02-27 filing 424B3
- 2025-02-27 filing Proxy statement
- 2025-02-27 filing 8-K items 1.01,9.01
- 2025-02-26 filing PRER14A
- 2025-02-14 filing PRE 14A
- 2025-01-23 filing SCHEDULE 13D/A
- 2025-01-22 filing 424B3
- 2025-01-22 filing 424B3
- 2025-01-22 filing 8-K items 1.01,7.01,9.01
- 2025-01-21 filing 424B3
- 2025-01-21 filing 424B3
- 2025-01-21 filing 8-K items 8.01
- 2025-01-17 filing 424B3
- 2025-01-17 filing 424B3
- 2025-01-17 filing Quarterly report (10-Q)
- 2025-01-06 filing SCHEDULE 13D/A
- 2025-01-03 filing 424B3
- 2025-01-03 filing 424B3
- 2025-01-03 filing 8-K items 1.01,9.01
- 2024-12-30 filing 8-K items 7.01,9.01
- 2024-12-13 filing 424B3
- 2024-12-13 filing 424B3
- 2024-12-13 filing 8-K items 1.01,8.01,9.01
- 2024-12-13 filing 424B5
- 2024-12-10 filing 8-K items 7.01,9.01
- 2024-12-10 filing 424B3
- 2024-12-10 filing 424B3
- 2024-12-10 filing 424B3
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-17 (within 7 days) NT 10-Q filed
- 2026-11-17 (within 7 days) 8-K filed: Item 4.01 auditor change
- 2026-09-29 (older) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-08-14 (older) 10-Q filed
- 2026-08-12 (older) 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-07-22 (older) 8-K filed: Item 1.01 material agreement; Item 2.01 acquisition or disposition; Item 9.01 exhibits
- 2026-07-06 (older) 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-30 (older) S-8 filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:SCLX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1820190 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | SCLX / Nasdaq, Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 529900SPEA2C7YTTYP45 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 529900SPEA2C7YTTYP45) | GLEIF |
| CUSIP | 86633R609 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001820190 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $30,253,000 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-20 10:23 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$374,053,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 10:23 UTC | Report an error |
| Total assets (at 2025-12-31) | $364,981,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 10:23 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | -$207,781,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $4,955,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 10:23 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| State of incorporation | DE | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Business address | 960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303 | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
| Exchanges | Nasdaq, Nasdaq | 2026-11-17 | SEC EDGAR company profile | as filed | 2026-11-20 10:23 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $3,816,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 10:23 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $133,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 10:23 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $14,884,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D total offering amount (D filed 2025-10-14) | $2,688,540 | 2025-10-14 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D total amount sold (D filed 2025-10-14) | $2,688,540 | 2025-10-14 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D industry group | Biotechnology | 2025-10-14 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D revenue range | $25,000,001 - $100,000,000 | 2025-10-14 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
| Form D date of first sale | 2025-09-30 | 2025-10-14 | D | as filed | 2026-11-20 10:23 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-06-30, filed 2026-08-14 · accession 0001193125-26-352464
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $7,642,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-14 | 0001193125-26-352464 | 2026-11-20 10:23 UTC | Report an error |
| Net income (loss) | -$114,986,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-14 | 0001193125-26-352464 | 2026-11-20 10:23 UTC | Report an error |
| Interest expense | $6,104,000 | 3 months ended 2026-06-30 | 10-Q | 2026-08-14 | 0001193125-26-352464 | 2026-11-20 10:23 UTC | Report an error |
| Cash and cash equivalents | $566,000 | at 2026-06-30 | 10-Q | 2026-08-14 | 0001193125-26-352464 | 2026-11-20 10:23 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-17 Filing NT 10-Q filed
- 2026-11-17 Filing 8-K filed: Item 4.01 auditor change
- 2026-09-29 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-08-14 Filing 10-Q filed
- 2026-08-12 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-07-22 Filing 8-K filed: Item 1.01 material agreement; Item 2.01 acquisition or disposition; Item 9.01 exhibits
- 2026-07-06 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-30 Filing S-8 filed
- 2026-06-29 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale
- 2026-06-24 Filing 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-06-11 Filing EFFECT filed
- 2026-06-09 Filing CORRESP filed
- 2026-06-09 Filing UPLOAD filed
- 2026-06-02 Filing S-3 filed
- 2026-05-22 Filing EFFECT filed
- 2026-05-20 Filing 10-Q filed
- 2026-05-20 Filing CORRESP filed
- 2026-05-15 Filing NT 10-Q filed
- 2026-05-11 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-05 Filing DEFA14A filed
- 2026-05-05 Filing 8-K filed: Item 1.01 material agreement; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-30 Filing ARS filed
- 2026-04-30 Filing DEF 14A filed
- 2026-04-30 Filing CORRESP filed
- 2026-04-28 Filing 8-K filed: Item 1.01 material agreement
8-K item text, as filed (excerpts)
- 2026-11-17 8-K Item 4.01, Changes in Registrant’s Certifying Accountant
Dismissal of Independent Registered Public Accounting Firm On November 11, 2026, the audit committee (the “Committee”) of the board of directors of Scilex Holding Company (the “Company”) approved the dismissal of BPM LLP (“BPM”) as the Company’s independent registered public accounting firm. The Company notified BPM of the dismissal on November 16, 2026. The reports of BPM on the consolidated financial statements of the Company for the fiscal years ended December 31, 2025 and December 31, 2024 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except for an explanatory paragraph in each… the 8-K · retrieved 2026-11-20 10:23 UTC - 2026-09-29 8-K Item 1.01, Entry into a Material Definitive Agreement
As previously disclosed, on August 8, 2026, Scilex Holding Company (the “Company”) entered into a Promissory Note (Revolving Line of Credit) (the “Note”) with Vivasor, Inc. (“Vivasor”), as borrower, pursuant to which the Company established in favor of Vivasor an uncommitted revolving line of credit in a maximum aggregate principal amount of up to $20,000,000 (the “Maximum Credit Amount”). On September 25, 2026, the Company and Vivasor entered into an amendment to the Note (the “Amendment”), pursuant to which the Maximum Credit Amount was increased from $20,000,000 to $30,000,000. No other changes were made to the Note. Dr. Henry Ji, Ph.D., the Company’s current Chief Executive Officer… the 8-K · retrieved 2026-11-20 10:23 UTC - 2026-08-12 8-K Item 1.01, Entry into a Material Definitive Agreement
On August 8, 2026 (the “Effective Date”), Scilex Holding Company (the “Company”) entered into a Promissory Note (Revolving Line of Credit) (the “Note”) with Vivasor, Inc. (“Vivasor”), as borrower, pursuant to which the Company established in favor of Vivasor an uncommitted revolving line of credit in a maximum aggregate principal amount of up to $20,000,000 (the “Maximum Credit Amount”). The Note has a stated maturity of 120 months from the Effective Date (the “Maturity Date”). The Note evidences a revolving credit facility under which Vivasor may, from time to time prior to the Maturity Date, request advances (“Drawdowns”) in multiple borrowings, provided that the aggregate outstanding… the 8-K · retrieved 2026-11-20 10:23 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | $9,339,129 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 2 | BlackRock, Inc. | $4,030,064 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 3 | VANGUARD FIDUCIARY TRUST CO | $1,310,285 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 4 | STATE STREET CORP | $1,088,216 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 5 | UBS Group AG | $826,730 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 6 | Themes Management Co LLC | $627,367 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 7 | NORTHERN TRUST CORP | $477,345 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 8 | Balyasny Asset Management L.P. | $230,875 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | $186,888 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
| 10 | FRANKLIN RESOURCES INC | $181,222 | 2026-06-30 | SEC 13F filing | 2026-11-20 10:23 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- SCILEX HOLDING COMPANY · LEI 529900SPEA2C7YTTYP45 · root
Exhibit 21 subsidiaries: not held yet.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1820190.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001820190. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.